[10]-Shogaol

[10]-Shogaol is an orally active antioxidant. [10]-Shogaol can be extracted from ginger (Zingiber officinale). [10]-Shogaol1 inhibits COX-2 with an IC₅₀ value of 7.5 μM. [10]-Shogaol inhibits the production of proinflammatory cytokines (IL-1β, IL-6). [10]-Shogaol inhibits NF-κB phosphorylation. [10]-Shogaol has anti-inflammatory effects. [10]-Shogaol has anticancer effects against Docetaxel (HY-B0011)-resistant prostate cancer. [10]-Shogaol exhibits larvicidal activity against L5 larvae of Angiostrongylus cantonensis^{[1][2][3][4][5]}. IC50 & Target:IC50: 7.5 μM (COX-2)^[2] In Vitro:[10]-Shogaol (2-10 μM; 12-24 h) promotes the migration and emigration of normal human epidermal keratinocytes and dermal fibroblasts^[1].
[10]-Shogaol (2-10 μM) enhances the production of TGF-β, PDGF-αβ, and VEGF in both human normal epidermal keratinocytes and dermal fibroblasts^[1].
[10]-Shogaol inhibits COX-2 with an IC₅₀ of 7.5 μM^[2].
[10]-Shogaol (100 μM; 24 h) inhibits proliferation of Docetaxel (HY-B0011)-resistant prostate cancer cells (PC3R) and downregulates MRP1 and GSTπ protein expression ^[3].
[10]-Shogaol (1-200 μM; 24-72 h) shows larvicidal activity against Angiostrongylus cantonensis L5 larvae in a time- and dose-dependent manner^[4]. In Vivo:[10]-Shogaol (30 mg/kg; p.o.,; 2 weeks) ameliorates DSS-induced colitis in mice by inhibiting inflammation, protecting intestinal barrier function, and regulating NF-κB signaling pathway^[5].